Header Logo

Cristina Arriens

TitleClinical Assistant Member
InstitutionOklahoma Medical Research Foundation
DepartmentArthritis and Clinical Immunology
825 N.E. 13th Street
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jog NR, Wagner CA, Aberle T, Chakravarty EF, Arriens C, Guthridge JM, James JA. Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype. Front Immunol. 2024; 15:1339250. PMID: 38524128; PMCID: PMC10957542.
      Citations:    Fields:    Translation:HumansCells
    2. Slight-Webb S, Thomas K, Smith M, Wagner CA, Macwana S, Bylinska A, Donato M, Dvorak M, Chang SE, Kuo A, Cheung P, Kalesinskas L, Ganesan A, Dermadi D, Guthridge CJ, DeJager W, Wright C, Foecke MH, Merrill JT, Chakravarty E, Arriens C, Maecker HT, Khatri P, Utz PJ, James JA, Guthridge JM. Ancestry-based differences in the immune phenotype are associated with lupus activity. JCI Insight. 2023 08 22; 8(16). PMID: 37606045; PMCID: PMC10543734.
      Citations:    Fields:    Translation:HumansCells
    3. Saxena A, Ginzler EM, Gibson K, Satirapoj B, Zuta Santill?n AE, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2023 Jul 19. PMID: 37466424.
      Citations: 5     Fields:    Translation:Humans
    4. Askanase AD, Aranow C, Kim MY, Kamen DL, Arriens C, Khalili L, Tang W, Barasch J, Dall'Era M, Mackay M. Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus Sci Med. 2023 07; 10(2). PMID: 37429672; PMCID: PMC10335468.
      Citations:    Fields:    Translation:HumansPHPublic Health
    5. Munroe ME, Blankenship D, DeFreese D, Purushothaman M, DeJager W, Macwana S, Guthridge JM, Kamp S, Redinger N, Aberle T, Chakravarty EF, Arriens C, Li Y, Zeng H, McCarthy-Fruin KA, Osei-Onomahm SA, Thanarajasingam U, James JA, Jupe E. A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 Oct 17. PMID: 36245261; PMCID: PMC10106527.
      Citations:    Fields:    Translation:Humans
    6. Arriens C, Teng YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, Gibson K, Caster DJ, Atsumi T, Lisk L, Randhawa S, Gluck R, Solomons N, Huizinga RB. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care Res (Hoboken). 2022 Aug 30. PMID: 36039949.
      Citations: 3     Fields:    Translation:Humans
    7. Wood RA, Guthridge L, Thurmond E, Guthridge CJ, Kheir JM, Bourn RL, Wagner CA, Chen H, DeJager W, Macwana SR, Kamp S, Lu R, Arriens C, Chakravarty EF, Thanou A, Merrill JT, Guthridge JM, James JA. Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmun. 2021; 4:100117. PMID: 35005588.
      Citations: 5     
    8. Bagavant H, Araszkiewicz AM, Ingram JK, Cizio K, Merrill JT, Arriens C, Guthridge JM, James JA, Deshmukh US. Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. Front Immunol. 2021; 12:635072. PMID: 34122404.
      Citations: 9     Fields:    Translation:HumansCells
    9. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 05 29; 397(10289):2070-2080. PMID: 33971155.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    10. Ramsey-Goldman R, Alexander RV, Conklin J, Arriens C, Narain S, Massarotti EM, Wallace DJ, Collins CE, Saxena A, Putterman C, Brady K, Kalunian KC, Weinstein A. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. ACR Open Rheumatol. 2021 Feb; 3(2):116-123. PMID: 33538130.
      Citations: 1     
    11. Almaani S, Bhatt U, Arriens C, Bonfa E, Dall'Era M, Houssiau F, Kalunian K, Mackay M, Sanchez-Guerrero J, Solomons N, Rovin BH. Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney Int Rep. 2020 Aug; 5(8):1302-1305. PMID: 32775830.
    12. Slight-Webb S, Smith M, Bylinska A, Macwana S, Guthridge C, Lu R, Merrill JT, Chakravarty E, Arriens C, Munroe ME, Maecker HT, Utz PJ, Guthridge JM, James JA. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433. PMID: 32446964.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    13. Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 04; 7(1). PMID: 32371480.
      Citations: 3     Fields:    Translation:HumansCells
    14. Arriens C, Aberle T, Carthen F, Kamp S, Thanou A, Chakravarty E, James JA, Merrill JT, Ogunsanya ME. Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360. PMID: 32201595.
      Citations: 10     Fields:    Translation:Humans
    15. Guthridge JM, Lu R, Tran LT, Arriens C, Aberle T, Kamp S, Munroe ME, Dominguez N, Gross T, DeJager W, Macwana SR, Bourn RL, Apel S, Thanou A, Chen H, Chakravarty EF, Merrill JT, James JA. Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine. 2020 Mar; 20:100291. PMID: 32154507.
      Citations: 20     
    16. Thanou A, James JA, Arriens C, Aberle T, Chakravarty E, Rawdon J, Stavrakis S, Merrill JT, Askanase A. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci Med. 2019; 6(1):e000365. PMID: 31921432.
      Citations: 11     Fields:    
    17. Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O'Malley T, Dervieux T, Weinstein A. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 01; 72(1):78-88. PMID: 31469249.
      Citations: 17     Fields:    Translation:HumansCells
    18. Karp DR, Chong BF, James JA, Arriens C, Ishimori M, Wallace DJ, Liao D, Olsen NJ. Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken). 2019 11; 71(11):1425-1429. PMID: 30369087.
      Citations: 1     Fields:    Translation:Humans
    19. Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis Rheumatol. 2019 03; 71(3):411-419. PMID: 30225865.
      Citations: 16     Fields:    Translation:Humans
    20. Olsen NJ, James JA, Arriens C, Ishimori ML, Wallace DJ, Kamen DL, Chong BF, Liao D, Chinchilli VM, Karp DR. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018 Dec 20; 19(1):694. PMID: 30572906.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    21. Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford). 2017 04 01; 56(suppl_1):i32-i45. PMID: 28013203.
      Citations: 38     Fields:    Translation:Humans
    22. Arriens C, Chen S, Karp DR, Saxena R, Sambandam K, Chakravarty E, James JA, Merrill JT. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9. PMID: 27923701.
      Citations: 8     Fields:    Translation:Humans
    23. Wu T, Ding H, Han J, Arriens C, Wei C, Han W, Pedroza C, Jiang S, Anolik J, Petri M, Sanz I, Saxena R, Mohan C. Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. J Proteome Res. 2016 07 01; 15(7):2102-14. PMID: 27211902.
      Citations: 29     Fields:    Translation:Humans
    24. Orme JJ, Du Y, Vanarsa K, Mayeux J, Li L, Mutwally A, Arriens C, Min S, Hutcheson J, Davis LS, Chong BF, Satterthwaite AB, Wu T, Mohan C. Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol. 2016 08; 169:58-68. PMID: 27237127.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    25. Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015 Oct; 27(10):1154-60. PMID: 26148245.
      Citations: 12     Fields:    Translation:Humans
    26. Arriens C, Hynan LS, Lerman RH, Karp DR, Mohan C. Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus. Nutr J. 2015 Aug 18; 14:82. PMID: 26283629.
      Citations: 33     Fields:    Translation:Humans
    27. Hutcheson J, Ye Y, Han J, Arriens C, Saxena R, Li QZ, Mohan C, Wu T. Resistin as a potential marker of renal disease in lupus nephritis. Clin Exp Immunol. 2015 Mar; 179(3):435-43. PMID: 25345756.
      Citations: 22     Fields:    Translation:HumansCells
    28. Arriens C, Mohan C. Systemic lupus erythematosus diagnostics in the 'omics' era. Int J Clin Rheumtol. 2013 Dec 01; 8(6):671-687. PMID: 24860621.
      Citations: 18     
    Arriens's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (146)
    Co-Authors (15)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors